Prostatype Genomics ABOSTO:PROGEN -4.23%25 Quick Ratio is 0.43 as of Dec. 2025, which is 71% below its 10-year median of 1.48. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks worse than 92.99% on this metric.
Prostatype Genomics AB has a quick ratio of 0.43. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Prostatype Genomics AB's Quick Ratio or its related term are showing as below:
OSTO:PROGEN'
s Quick Ratio Range Over the Past 10 Years
Min: 0.43 Med: 1.48 Max: 6.26
Current: 0.43
During the past 7 years, Prostatype Genomics AB's highest Quick Ratio was 6.26. The lowest was 0.43. And the median was 1.48.
OSTO:PROGEN's Quick Ratio is ranked worse than 92.99% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.715
vs OSTO:PROGEN: 0.43
Prostatype Genomics AB (OSTO:PROGEN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Prostatype Genomics AB Quick Ratio Related Terms
Prostatype Genomics AB Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: Quick Ratio Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Prostatype Genomics AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) has a Quick Ratio of 0.43 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Prostatype Genomics AB and its competitors. This is 71% below median its historical median of 1.48. Over the past decade, Prostatype Genomics AB's Quick Ratio has ranged from 0.43 to 6.26. According to the industry distribution chart, Prostatype Genomics AB ranks #199 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 93%.
Is Prostatype Genomics AB's Quick Ratio too high?
Prostatype Genomics AB's current Quick Ratio of 0.43 is 71% below median its 10-year median of 1.48. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 6.26. The Medical Diagnostics & Research industry median Quick Ratio is 1.72. Prostatype Genomics AB's value of 0.43 is 74.9% below this industry median. Based on the distribution chart, Prostatype Genomics AB ranks #199 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #199 out of 214 companies for Quick Ratio. This places Prostatype Genomics AB in the lower half of its industry. The industry median Quick Ratio is 1.72. Prostatype Genomics AB's value of 0.43 is 74.9% below this benchmark. Historically, Prostatype Genomics AB's own Quick Ratio has ranged from 0.43 to 6.26 over the past decade. While the company's 10-year median is 1.48 vs. the industry median of 1.72, Prostatype Genomics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.72, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostatype Genomics AB's current Quick Ratio of 0.43 is 74.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current Quick Ratio is 0.43, which is 71% below median its own 10-year median of 1.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.43 — trading 290.9% above its estimated fair value. The current Quick Ratio is 0.43, which is 71% below median its 10-year median of 1.48 and 74.9% below the Medical Diagnostics & Research industry median of 1.72. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Quick Ratio is 0.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.43 is trading 290.9% above its estimated GF Value™ of kr0.11.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
Quick Ratio: 0.43 (71% below median its 10-year median of 1.48)
GF Value™: kr0.11 vs. price of kr0.43 (290.9% above fair value)
Industry Position: 74.9% below the Medical Diagnostics & Research median (#199 of 214)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score
Get the complete analysis for OSTO:PROGEN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
